Nanotechnology Now

Our NanoNews Digest Sponsors


Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Abraxis Health Dedicates State of the Art Nanotechnology & Biologics Facility in Phoenix, Arizona

Abstract:
Flagship Facility Compliant with Worldwide Nanobiologics Regulatory Requirements

Abraxis Health Dedicates State of the Art Nanotechnology & Biologics Facility in Phoenix, Arizona

Los Angeles, CA | Posted on November 5th, 2009

Abraxis Health, a fully-integrated personalized healthcare division of Abraxis BioScience, Inc. (NASDAQ:ABII), today announced the dedication of its new manufacturing facility in Phoenix, Arizona. The state of the art biopharma manufacturing plant represents a $70 million investment by LA-based Abraxis, and will create up to 200 high tech jobs. The new facility will manufacture ABRAXANE®, the first solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using Abraxis BioScience's proprietary nab® technology platform. The company now has multiple agreements in place for the development of novel, insoluble compounds using the nanobiologics technology employed at the Phoenix plant.

The facility will be the world's largest and most sophisticated protein nanobiologics manufacturing plant, with annual production capacity of over 10 million units, and the capability to expand to 20 million units, suitable for worldwide distribution. The site, formerly owned by Watson Pharmaceuticals, was purchased by Abraxis in July 2007. Abraxis has hired more than 100 former Watson employees, recruited additional staff from among the local skilled workforce, and will continue to recruit as the facility ramps up production.

"The outlook for Abraxis is immensely encouraging," said founder and Chairman Dr. Patrick Soon-Shiong. "As we continue to grow, these new premises in Phoenix will become the flagship manufacturing facility for our cutting edge technology."

State Attorney General Terry Goddard commented, "Arizona is proud to welcome Abraxis as a powerful new addition to our growing life sciences sector."

"This is great news for Phoenix," said Mayor Phil Gordon. "We are delighted that Abraxis has chosen our city for this state of the art nanotech manufacturing plant, bringing highly skilled jobs and a welcome boost for our economy."

State, city and business leaders attended today's ceremony to dedicate the new facility, including Attorney General Goddard and Mayor Phil Gordon.

####

About Abraxis BioScience
Abraxis Health, which will operate the Phoenix facility, is a division of Abraxis Bioscience Inc. Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company's portfolio includes the world's first and only protein-bound nanoparticle chemotherapeutic compound (ABRAXANE®), which is based on the company's proprietary tumor targeting technology known as the nab® platform. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer and is now approved in 38 countries. The company continues to expand the nab platform through a robust clinical program and deep product pipeline. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

For more information, please click here

Contacts:
Investors and Media Inquiries:
Abraxis BioScience, Inc.
Maili Bergman, 310-883-1300

Copyright © Abraxis BioScience

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

GLOBALFOUNDRIES to Expand Presence in China with 300mm Fab in Chongqing: Company plans new manufacturing facility and additional design capabilities to serve customers in China May 31st, 2016

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Jobs

SUNY Poly Welcomes DPS as the Global Engineering Firm Opens Its U.S. Advanced Technology Group Headquarters at Cutting-Edge ZEN Building November 20th, 2015

SUNY Poly CNSE Announces Milestone as M+W Group Opens U.S. Headquarters at Albany Nanotech Complex and Research Alliance Begins $105M Solar Power Initiative October 20th, 2015

Global Engineering Firm DPS to Establish U.S. Advanced Technology Group Headquarters at SUNY Poly CNSE and Create 56 New Jobs Under STARTUP-NY Initiative October 6th, 2015

SUNY Poly Announces Joint Development Agreement with INFICON to Establish Cutting Edge R&D Partnership Supporting New York State’s Rapidly Expanding Nanoelectronics Industry September 23rd, 2015

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events May 10th, 2016

ORIG3N Added to Companies Presenting at Harris & Harris Group's Annual Meeting, Tuesday June 7, 2016, the New York Genome Center April 27th, 2016

Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016

Harris & Harris Group Announces Formation of Co-Investment Fund for Accredited Investors March 9th, 2016

Nanomedicine

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

Announcements

GLOBALFOUNDRIES to Expand Presence in China with 300mm Fab in Chongqing: Company plans new manufacturing facility and additional design capabilities to serve customers in China May 31st, 2016

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

UK NANOSAFETY GROUP publishes 2nd Edition of guidance to support safe working with nanomaterials May 30th, 2016

Fast, stretchy circuits could yield new wave of wearable electronics May 30th, 2016

Industrial

GLOBALFOUNDRIES to Expand Presence in China with 300mm Fab in Chongqing: Company plans new manufacturing facility and additional design capabilities to serve customers in China May 31st, 2016

Finding a new formula for concrete: Researchers look to bones and shells as blueprints for stronger, more durable concrete May 26th, 2016

Solliance realizes first up-scaled Perovskite based PV modules with 10% efficiency: Holst Centre, imec and ECN pave the road to upscaling Perovskite PV modules May 10th, 2016

First single-enzyme method to produce quantum dots revealed: Biological manufacturing process, pioneered by three Lehigh University engineers, produces equivalent quantum dots to those made chemically--but in a much greener, cheaper way May 9th, 2016

Nanobiotechnology

Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31st, 2016

Automating DNA origami opens door to many new uses: Like 3-D printing did for larger objects, method makes it easy to build nanoparticles out of DNA May 30th, 2016

Simple attraction: Researchers control protein release from nanoparticles without encapsulation: U of T Engineering discovery stands to improve reliability and fabrication process for treatments to conditions such as spinal cord damage and stroke May 28th, 2016

Scientists illuminate a hidden regulator in gene transcription: New super-resolution technique visualizes important role of short-lived enzyme clusters May 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic